Allurion Announces Collaboration Agreement with Medtronic to Expand Access to AI-Powered W********** Program

Allurion, a company dedicated to ending obesity announced a pilot collaboration agreement with Medtronic a global leader in healthcare technology, to expand access to Allurion’s AI-powered w********** program through a sales agency agreement in the Central and Eastern Europe, Middle East, and Africa (CEMA) region. The partnership enables Allurion to offer the Allurion Balloon and accelerate utilization of the Allurion Iris Artificial Intelligence (AI) Platform in the management of bariatric surgery patients by leveraging Medtronic channels during the collaboration.

Top AI Interviews: AiThority Interview with James Rubin, Product Manager at Google

“We also believe this partnership will help accelerate adoption of our Iris AI Platform as a standalone offering to streamline the management of patients undergoing bariatric surgery and potentially improve outcomes, further cementing our position as a leader in AI and weight management.”

The Allurion Program combines the Allurion Balloon, the world’s first and only swallowable, procedure-less gastric balloon for w********** with the Allurion Virtual Care Suite, a remote patient monitoring solution powered by the Allurion Iris AI Platform and the company’s proprietary behavior change program. The Allurion Virtual Care Suite is also available to providers as a standalone product to help customize, monitor and manage w********** therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional.

In February 2023, Allurion announced its intention to go public via a business combination with Compute Health. Medtronic is currently an investor in Compute Health, and this agreement builds upon that existing relationship.

Latest Insights: How to Get Started with Prompt Engineering in Generative AI Projects

“We are thrilled to join forces with Medtronic to expand access to our w********** program. Medtronic has exceptional distribution capabilities across a number of different channels that can augment our base business,” said Dr. Shantanu Gaur, Allurion’s Founder and CEO. “We also believe this partnership will help accelerate adoption of our Iris AI Platform as a standalone offering to streamline the management of patients undergoing bariatric surgery and potentially improve outcomes, further cementing our position as a leader in AI and weight management.”

Recommended: AiThority Interview with Ramsey Masri, Chief Executive Officer at Ceres Imaging

[To share your insights with us, please write to sghosh@martechseries.com]